Member States should efficiently assess all clinical trials applications within the given timelines. A rapid yet in-depth assessment is of particular importance for clinical trials concerning medical conditions which are severely debilitating and/or life threatening and for which therapeutic options are limited or non-existent, as in the case of rare and ultra-rare diseases.
Recital 10, Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 20…
In forcesince 16 Apr 2014